Detalles de la búsqueda
1.
Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
Cephalalgia
; 44(2): 3331024241235156, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38410850
2.
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial.
J Headache Pain
; 25(1): 83, 2024 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38773375
3.
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
Cephalalgia
; 43(1): 3331024221128250, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36620892
4.
The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression.
J Headache Pain
; 24(1): 54, 2023 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37193973
5.
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
Cephalalgia
; 42(10): 1005-1012, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35332807
6.
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
Cephalalgia
; 42(8): 696-704, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35302389
7.
Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
Cephalalgia
; 42(8): 769-780, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35331009
8.
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
BMC Neurol
; 22(1): 205, 2022 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35659622
9.
A genomic history of Aboriginal Australia.
Nature
; 538(7624): 207-214, 2016 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27654914
10.
Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
J Headache Pain
; 23(1): 112, 2022 Aug 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36038833
11.
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
J Headache Pain
; 23(1): 22, 2022 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35130832
12.
Timing and durability of response to erenumab in patients with episodic migraine.
Headache
; 61(10): 1553-1561, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34841526
13.
Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.
Qual Life Res
; 30(2): 455-464, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32944843
14.
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
JAMA
; 325(23): 2348-2356, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34128999
15.
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States.
J Headache Pain
; 22(1): 156, 2021 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34930112
16.
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
Cephalalgia
; 40(1): 28-38, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31816249
17.
The Headache Pipeline: Excitement and Uncertainty.
Headache
; 60(1): 190-199, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31889312
18.
Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.
Headache
; 59(6): 880-890, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30977520
19.
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
BMC Neurol
; 23(1): 318, 2023 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37674117
20.
Periorbital necrotising soft tissue infection in a 12-year-old patient.
Scott Med J
; 63(3): 87-90, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29806539